Phase II, Prospective, Multinational, Multi-Center, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer (PROTACT)
The purpose of this phase II study is to assess the response rate of siG12D-LODER with chemotherapy treatment (gemcitabine+nab-paclitaxel) in patients with unresectable, locally advanced pancreatic cancer.
For more information about the study, please visit: http://pancan-protact.com/
Study ID: SLSG12D-P2
Trial Phase: Phase II
Trial Sponsor: Silenseed Ltd.
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, siG12D-LODER™